Advertisement
Advertisement
CTMX
CytomX Therapeutics, Inc.
3.46
USDSponsored
+0.09
+2.67%
Aug 07, 15:59 UTC -4
Closed
After-Market
3.46
0.00
+0.09%
CTMX Earnings Reports
Positive Surprise Ratio
CTMX beat 24 of 43 last estimates.
56%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$6.29M
/-$0.11
Implied change from Q2 26 (Revenue/ EPS)
+342.96%
/+22.22%
Implied change from Q3 25 (Revenue/ EPS)
+5.48%
/+22.22%
CytomX Therapeutics, Inc. earnings per share and revenue
On Aug 06, 2026, CTMX reported earnings of -0.09 USD per share (EPS) for Q2 26, missing the estimate of -0.07 USD, resulting in a -13.78% surprise. Revenue reached 1.42 million, compared to an expected 12.55 million, with a -88.69% difference. The market reacted with a +2.67% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.11 USD, with revenue projected to reach 6.29 million USD, implying an increase of 22.22% EPS, and increase of 342.96% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
Aligos Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.09
Actual
-$0.14
Surprise
+87.21%
FAQ
What were CytomX Therapeutics, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, CytomX Therapeutics, Inc. reported EPS of -$0.09, missing estimates by -13.78%, and revenue of $1.42M, -88.69% below expectations.
How did the market react to CytomX Therapeutics, Inc.'s Q2 2026 earnings?
The stock price moved up 2.67%, changed from $3.37 before the earnings release to $3.46 the day after.
When is CytomX Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for CytomX Therapeutics, Inc.'s next earnings report?
Based on 6
analysts, CytomX Therapeutics, Inc. is expected to report EPS of -$0.11 and revenue of $6.29M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement